anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: An agent for treatment of a skin disease comprising a substrate(or an edible substrate) and a thin film layer formed on one surface or the whole surface of the substrate is provided. Therefore, it has the function of treating acne or skin disorders and improving skin conditions and can be applied to the affected areas of the skin or orally administered. CONSTITUTION: A thin film layer(3) with a thickness of 5 Angstroms to 10 microns is coated on one surface or the whole surface of a substrate(1) with a moisture content of 30% or less to make a skin disease-treating agent. The thin film layer can be separated from the substrate by direct physical force and contains 2-99.99% silver. The substrate is prepared by blending oil, vaseline, honey, distilled water, plant extract, glycerine and commercial cosmetic(medicine, food) material. The thin film additionally contains at least one element of Ti, Si, Al, Cr, Zr, Zn, Sn, Au, Cu, oxides or nitrides thereof, A release layer such as a silicone thin film layer, a fluorine compound layer or an oil thin film layer is added between the thin film layer and the substrate.
A network-implemented integrated modeling system for genetic risk estimation uses guideline factor information and other input information to determine models usable for estimating genetic risk of disease in patients. Models are determined using established network connections with external sources. Health history information is collected from a patient, which is then processed against a relevant model to estimate the genetic risk of a disease corresponding to that model in that patient. Based on results of the estimation, a pedigree chart representing personal and family risk for the patient is generated and output to the patient and/or health care representatives of the patient. The results may be disseminated to one or more distributed computing environments from a central server which performs the genetic risk estimation. In some cases, follow-up validations performed using further collected data are used to update the constraints used to determine the models.
The C1 inhibitor will be used at a dose of 1000 units per slow infusion (two hours). Two infusions will be given 24 hours apart. These doses correspond to the usual doses used in the treatment of conditions in which the C1-Inhibitor is indicated.
Mutations in genes encoding proteins necessary for detoxifying oxidative stress products have been predicted to increase susceptibility to lung cancer (LC). Despite this, the association between waterpipe tobacco smoking (WP), genetic polymorphisms, and LC risk remains poorly understood. This is the first study to explore the relationship between WP tobacco smoking and these genetic factors. Previously, we investigated the association of GSTP1 SNPs (rs1695-A/G and rs1138272-C/T) with LC in Iraqi males who smoke WP. Here, we expanded our analysis to include GSTM1 (active/null) and GSTT1 (active/null) genotypes, both individually and in combination with GSTP1 SNPs. Multiplex PCR and RFLP-PCR assays were utilized to determine the genotypes of 123 cases and 129 controls. No significant association was observed between GSTM1-null or GSTT1-null genotypes and LC risk, either separately or in combination with variant genotypes of GSTP1 (rs1695 "AG+GG" and rs1138272 "CT+TT"). However, smoking WP and carrying null genotypes elevated the risk five-fold for GSTM1-null (OR 5.17, 95 % CI 2.02-13.24, P<0.001) and three-fold for GSTT1-null (OR 3.08, 95 % CI 1.55-6.13, P=0.001) compared to non-smokers carrying active genotypes. Conversely, genotype distribution analysis based on LC histological types did not indicate an increased risk of LC. Lung cancer is a complex multifactorial disease. WP smoking and GSTs genetic polymorphisms might be associated with an increased risk of developing LC. However, our data did not confirm an association between GST polymorphisms alone and the risk of LC.
After informing the patients and parents/guardians and checking the inclusion and exclusion criteria, the clinical data of the ill subjects are recorded and the HbA1c is measured in the laboratory as part of the routine recording. The blood collection is part of the routine diagnostics on presentation in the outpatient clinic and is performed separately from the study.

Subsequently, imaging by MSOT is performed in all study participants. This is performed on both sides of the lower leg over the triceps surae muscle. The examination is analogous to sonography over the corresponding skin layers without further invasive procedures. The anatomical region can be localized by means of built-in sonography; subsequently, the corresponding optoacoustic signals can be derived over it. This is followed by measurement of the Arm-Brachial-Index. After a short recovery time, the test persons perform a physical stress on the examined lower leg muscles. After renewed ABI measurement, the imaging examination is repeated using MSOT. Finally, the neurological status is assessed using the Neuropathy Disability Score (NSS).
The application of FDM for the treatment of non-specific subacute and chronic extremity pain in the ED combined with standard care holds enormous promise. High-quality studies investigating whether single-episode FDM therapy in the ED is effective are needed. Our goal is to conduct a randomized, prospective clinical trial investigating the use of FDM plus standard ED pain management for non-specific subacute and chronic extremity compared with standard ED pain management.

The anticipated outcome of this study is statistically and clinically significant improvement in function and pain in those treated with FDM compared with those compared with standard emergency department care alone for their extremity pain. Demonstration of such results would provide stronger evidence base for manual manipulation, particularly in the emergency department setting. This is a low-cost intervention that can be learned easily by physicians and providers of a variety of backgrounds (advanced care practitioners, physical therapists, etc.) and can thus provide an excellent alternative for pain management as opposed to our traditional approaches to pain such as rest, ice, compression, and elevation (RICE), and medications such as NSAID (non-steroidal anti-inflammatory drugs) and acetaminophen. We all realize that part of the reason we are struggling with an opioid epidemic in our country is that our traditional approaches to pain management are not always enough and that patients subsequently become dependent upon stronger medications for pain control that unfortunately have addictive properties as side effects. If FDM proves to be a successful intervention for managing subacute and chronic pain in the emergency department with a single treatment, imagine its applicability on a wider scale in the outpatient setting for chronic pain management and how this could help us combat the current opioid crisis.
The is a single center, open-label, 2 period crossover study randomized by route (intradermal versus subcutaneous) in patients with Type 1 diabetes. Subjects will receive their insulin, basal and bolus dosages, via intradermal (ID) and subcutaneous (SC) infusion sets over a three day period.

Each subject will participate in 3 visits: a Screening Visit (V1), followed by 2 experimental intervention days (V2 and V3) to be started 2 - 21 days after screening visit. The minimum/maximum interval between study days shall be 5 to 28 days. Each subject will remain in the clinic for approximately 3 days during the experimental interventions. A final exam will be performed at the end of Visit 3.

After successful screening and enrollment subjects are admitted to the clinic. Their insulin pump and infusion set is replaced by the investigational system, a commercially available insulin pump and either the intradermal infusion set (Research Catheter Set, BD) or the subcutaneous infusion set (Quick Set, Medtronic)to include an in-line pressure transducer/recorder and insulin NovoRapid. The initial pump infusion rate is established based on the patient's known basal infusion rate and the meal bolus insulin is estimated based on the patient's known insulin sensitivity. An intravenous (in the vein) catheter line is established, blood glucose is measured at least every 2 hours overnight and insulin corrections can be implemented, if deemed necessary. The overnight and pre-prandial (before meal) target range is 70-160 mg/dl, although the procedure will continue as planned if the patient is outside the range. It should be the goal not to give any IV glucose or insulin at all, and not to change basal insulin settings for at least 2 hours before the meal. The breakfast meal will be a high GI (60g carbohydrates) solid meal, to be consumed within 15 minutes and followed for a period of 6 hours of blood sampling for glucose and insulin levels. Lunch will be served as standardized mixed meal, and followed for a period of 4-6 hours. This procedure is repeated on days 2 and 3 whereas the breakfast and lunch meal as well as the insulin dose to cover the meal are the same. A light evening dinner is served every day, composition and insulin dose to be recorded. On day three after the 4 hour period following lunch the catheter will be removed, catheter and site assessments will be documented and an ultrasound observation of the infusion site (skin thickness and SC) versus an adjacent control site will be performed within 10 min after removal of the infusion set. Glucose rescue, if necessary, will be administered orally (juice, 200 mL). Insulin correction boli should be delivered via the investigational infusion set.
BACKGROUND: Total talus replacement (TTR) implants are designed to replace the diseased talar anatomy, reduce pain, maintain ankle range of motion, and restore ankle function after conservative treatments have failed. Currently TTR implants are produced by 3D printing a patient-specific implant designed from the patient's preoperative anatomy. TTR surgery using patient-specific implants is a relatively new technique that remains understudied in the literature. Therefore, the purpose of this investigation was to determine the early safety and potential benefit of the TTR implant in patients with talar avascular necrosis.
METHODS: This retrospective, multicenter, cohort study evaluates the safety and potential benefits of TTR using 3D-printed patient-specific implants across 4 US centers. The primary outcome was the occurrence of early adverse events after TTR surgery. Secondary outcomes including, pain, and physical function were assessed using the pain visual analog scale (VAS), and Patient-Reported Outcomes Measurement Information System (PROMIS) physical function (PF), respectively.
RESULTS: The study team analyzed 15 patients with more than 1 year of follow-up. The mean duration of follow-up was 25.9 months (range: 18.3-41 months). Although 33.3% (5 of 15) of patients experienced adverse events, primarily occurring within the initial 6 months postoperatively, 93% (14 of 15) of patients reported implant survivorship. Of the 5 cases (33.3%) resulting in an adverse event, 3 (60.0%) were determined to be unrelated to the subject device, 2 (40.0%) were determined to be possibly procedure-related, and none (0%) were determined to be device-related.
CONCLUSION: Although further studies are needed to compare TTR with the standard of care, the results of this study demonstrate the relative early safety of TTR surgery using a 3D-printed implant for the treatment of challenging talar pathologies. A larger and longer clinical study is required to see if the efficacy of this approach will be statistically and clinically meaningful.
A phosphatic mineral binder is prepared by dissolving a phosphate of aluminium, iron or nickel in sulphuric, nitric or hydrochloric acid and dehydrating the solution, either at about 150 DEG C. to form a clear solid, or at 125-130 DEG C. to form a clear viscous tacky liquid.  Alternatively, the solution may be formed by dissolving a sulphate, nitrate or chloride of the metal in phosphoric acid.  In an example aluminium chloride, prepared from bauxite and hydrochloric acid, is treated with phosphoric acid. The products may be used to bond bauxite, fuller's earth, activated carbon, silica gel, magnesium oxide, magnesium silicate, asbestos or feldspar.  They may also be used to modify clays and to form glass or porcelain type material with lime and silica.ALSO:A phosphatic mineral binder is prepared by dissolving a phosphate of aluminium, iron or nickel in sulphuric, nitric or hydrochloric acid and dehydrating the solution, either at about 150 DEG C. to form a clear solid, or at 125 DEG -130 DEG C. to form a clear viscous tacky liquid.  Alternatively the solution may be formed by dissolving a sulphate, nitrate or chloride of the metal in phosphoric acid.  In an example, aluminium chloride, prepared from bauxite and hydrochloric acid, is treated with phosphoric acid. The products may be used to bond bauxite, fuller's earth, activated carbon, silica gel, magnesium oxide, magnesium silicate, asbestos or feldspar.  They may also be used to modify clays and to form glass or porcelain type material with lime and silica.
The application discloses a colon cancer specific annular RNA marker, a detection primer and application thereof, and belongs to the technical field of biology. The application aims to provide a marker for diagnosis, screening or prognosis evaluation of colon cancer and a detection method thereof. In order to solve the technical problem, the application provides application of a molecular marker or a substance for detecting the molecular marker in preparation of a product for colon cancer diagnosis or auxiliary diagnosis, wherein the molecular marker is circRNA, and the nucleotide sequence of the molecular marker is shown as SEQ ID No. 1. The application establishes the detection method of the circRNA, and the method and the detection primer thereof have good amplification efficiency and specificity. The molecular marker and the detection method and the primer thereof have good and potential clinical application values in the aspects of diagnosis, auxiliary diagnosis, screening, auxiliary screening or prognosis evaluation of colon cancer and the like.
Intervention group participants (n=24) will receive the standard of care and complete a 16-week supervised physical activity/behaviour modification program at no cost. The first eight weeks of the program involves structured exercise (two per week) and education classes that patients must attend. Progression to a moderate/high-intensity interval program based the patient's capabilities will occur. Participants will also attend education sessions on risk factor reduction, healthy eating, exercise, stress management and promotion of self-managed care. During the second eight week period, participants will be given access to attend drop-in exercise classes or can opt to complete at home exercise. Participants will have an opportunity to meet with the kinesiologist on at least 4 occasions (60 minutes/meeting) for additional physical activity counseling and assistance with overcoming barriers preventing physical activity.
Outpatients – Therapy should be initiated at 75 mg/day. Dosage may be increased to 150 mg/day which is the dose level at which optimum response is usually obtained. If necessary, dosage may be increased to 200 mg/day. 

Dosage higher than 75 mg/day may also be administered on a once-a-day basis after the optimum dosage and tolerance have been determined. The daily dosage may be given at bedtime. In some patients it may be necessary to employ a divided-dose schedule. 

As with all tricyclics, the antidepressant effect of imipramine may not be evident for one to three weeks in some patients. 

Hospitalized Patients – Therapy should be initiated at 100 to 150 mg/day and may be increased to 200 mg/day. If there is no response after two weeks, dosage should be increased to 250 to 300 mg/day. 

Dosage higher than 150 mg/day may also be administered on a once-a-day basis after the optimum dosage and tolerance have been determined. The daily dosage may be given at bedtime. In some patients it may be necessary to employ a divided-dose schedule. 

As with all tricyclics, the antidepressant effect of imipramine may not be evident for one to three weeks in some patients. 

Adult Maintenance Dosage – Following remission, maintenance medication may be required for a longer period of time at the lowest dose that will maintain remission after which the dosage should gradually be decreased. 

The usual maintenance dosage is 75 to 150 mg/day. The total daily dosage can be administered on a once-a-day basis, preferably at bedtime. In some patients it may be necessary to employ a divided-dose schedule. 

In cases of relapse due to premature withdrawal of the drug, the effective dosage of imipramine should be reinstituted. 

Adolescent and Geriatric Patients – Therapy in these age groups should be initiated with Tofranil™, brand of imipramine hydrochloride tablets, at a total daily dosage of 25 to 50 mg, since imipramine pamoate capsules are not available in these strengths. Dosage may be increased according to response and tolerance, but it is generally unnecessary to exceed 100 mg/day in these patients. Imipramine pamoate capsules may be used when total daily dosage is established at 75 mg or higher. 

The total daily dosage can be administered on a once-a-day basis, preferably at bedtime. In some patients it may be necessary to employ a divided-dose schedule. 

As with all tricyclics, the antidepressant effect of imipramine may not be evident for one to three weeks in some patients. 

Adolescent and geriatric patients can usually be maintained at lower dosage. Following remission, maintenance medication may be required for a longer period of time at the lowest dose that will maintain remission after which the dosage should gradually be decreased. 

The total daily maintenance dosage can be administered on a once-a-day basis, preferably at bedtime. In some patients it may be necessary to employ a divided-dose schedule. 

In cases of relapse due to premature withdrawal of the drug, the effective dosage of imipramine should be reinstituted.
The invention provides a method of patient monitoring following endovascular aneurysm repair (EVAR) with a stent graft. It particularly applies to abdominal aortic aneurysm repair.  A first 3D volume scan of the stent in situ is provided and a second, subsequent 3D volume scan of the stent is also provided. One or more fiducial markers are generated in a first image derived from the first scan and in a second image derived from the second scan. The fiducial markers identify recognizable features of the stent, such as the bifurcation point in the stent graft. A rigid 3D transform mapping based on the one or more fiducial markers is extracted and then a registration is applied to the first and second scans based on the 3D rigid transform between the first and second images. A size-based parameter is derived at the same location in the aneurysm from the first and second scans. The same location is determined with reference to the registered first and second images of the stent. A comparison of the size-based parameter from the first and second scans is used to assess a change in size of the aneurysm between the first and second scans. This change in size allows the clinician to evaluate disease progression.
Immobilization of extremities after stroke causes articular cartilage degeneration. Likewise, since patients tend to transfer weight to the non-paretic extremity, a load difference occurs between the lower extremity joints. Therefore, it is thought that the femoral cartilage thickness will be affected in stroke patients. Considering this information, it is thought that the femoral cartilage thickness will be different between the paretic and non-paretic extremities, and also between stroke patients with and without knee hyperextension in the stance phase. Accordingly, the first aim of this study is to measure knee hyperextension and femoral cartilage thickness (paretic and nonparetic side) of stroke patients. The second aim is to compare the femoral cartilage thickness of the paretic and nonparetic extremities and in stroke patients with and without knee hyperextension.
Necrotising fasciitis (NF) is an uncommon surgical emergency that threatens the life and health of patients. We report the treatment of a 76-year-old female patient with NF. The patient developed NF due to chronic poor glycaemic control, which further progressed to multiple organ dysfunction syndrome due to the severity of the hyperglycaemia. After resuscitation at the intensive care unit, surgical treatment was recommended and the patient underwent laparoscopic surgery. She had an uneventful post-operative recovery with aggressive anti-inflammatory therapy, glycaemic control and systemic nutritional support. There were no recurrences during the next 6 months of follow-up. NF should be diagnosed and treated as early as possible to gain valuable treatment time for the patient. Laparoscopic surgery is a treatment option.
PROBLEM TO BE SOLVED: To obtain the subject flexible and soft substrate not giving a foreign touch to a human body, when adhered to the human body, and not giving an injurious substance to the human body by adhering a specific thin nonwoven fabric to a thin film. SOLUTION: This substrate is obtained by adhering a nonwoven fabric comprising polyester (polyethylene terephthalate, etc.) staple fibers and preferably having a base weight of 20-50g/m<2> to a polyester film preferably having a thickness of 5-12μm through a hydrophobic polyester resin. The adhesion is carried out with a minimized amount of a hydrophobic polyester resin adhesive little in hot water extract so as to maintain a peeling strength necessary for practical use. The hydrophobic polyester resin includes Vylon (R) [registered trade mark, made by Toyo Spinning (limited)] G200. When coated with a transdermally absorbable medicine and adhered to a human body, the substrate does not give a foreign touch to the human body, does not give an injurious substance to the human body, and is soft and rich in safety.
Participants randomised to the intervention arm will receive a CBT informed, self-help intervention for anxiety in PH. This will be based on the four factor model, which is a trans-diagnostic approach to help understanding and identify behaviour change methods (Padesky \& Mooney, 1990).
The No RIC group will receive a sham intervention at all the same time points. The thigh tourniquet will be inflated to only 20 mmHg (to mask the intervention from the subject).
Fat accumulation, de novo lipogenesis, and glycolysis are key drivers of hepatocyte reprogramming and the consequent metabolic dysfunction-associated steatotic liver disease (MASLD). Here we report that obesity leads to dysregulated expression of hepatic protein-tyrosine phosphatases (PTPs). PTPRK was found to be increased in steatotic hepatocytes in both humans and mice, and correlates positively with PPARγ-induced lipogenic signaling. High-fat-fed PTPRK knockout male and female mice have lower weight gain and reduced hepatic fat accumulation. Phosphoproteomic analysis in primary hepatocytes and hepatic metabolomics identified fructose-1,6-bisphosphatase 1 and glycolysis as PTPRK targets in metabolic reprogramming. Mechanistically, PTPRK-induced glycolysis enhances PPARγ and lipogenesis in hepatocytes. Silencing PTPRK in liver cancer cell lines reduces colony-forming capacity and high-fat-fed PTPRK knockout mice exposed to a hepatic carcinogen develop smaller tumours. Our study defines the role of PTPRK in the regulation of hepatic glycolysis, lipid metabolism, and tumour development in obesity.